WBB Securities Reiterates Strong-Buy Rating for Marker Therapeutics (NASDAQ:MRKR)

Marker Therapeutics (NASDAQ:MRKR)‘s stock had its “strong-buy” rating reissued by investment analysts at WBB Securities in a note issued to investors on Tuesday,Benzinga reports. They presently have a $12.50 price objective on the stock.

MRKR has been the subject of several other research reports. Canaccord Genuity Group assumed coverage on Marker Therapeutics in a research note on Wednesday, March 5th. They issued a “buy” rating and a $8.00 price target for the company. Brookline Capital Management upgraded Marker Therapeutics to a “strong-buy” rating in a report on Monday, February 10th.

Marker Therapeutics Trading Up 5.3 %

Shares of NASDAQ MRKR opened at $1.20 on Tuesday. The company has a 50 day simple moving average of $1.57 and a 200 day simple moving average of $2.70. Marker Therapeutics has a 1 year low of $1.10 and a 1 year high of $5.99.

Marker Therapeutics (NASDAQ:MRKR) last released its quarterly earnings results on Monday, March 31st. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.14). Marker Therapeutics had a negative net margin of 179.74% and a negative return on equity of 89.63%. The business had revenue of $1.22 million for the quarter, compared to the consensus estimate of $5.25 million. As a group, research analysts expect that Marker Therapeutics will post -0.65 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in MRKR. NEA Management Company LLC grew its stake in Marker Therapeutics by 51.7% during the fourth quarter. NEA Management Company LLC now owns 1,625,678 shares of the company’s stock worth $5,056,000 after purchasing an additional 554,250 shares during the period. Millennium Management LLC bought a new position in shares of Marker Therapeutics during the 4th quarter worth approximately $50,000. Alyeska Investment Group L.P. acquired a new stake in shares of Marker Therapeutics during the 4th quarter worth approximately $2,847,000. Northern Trust Corp increased its stake in shares of Marker Therapeutics by 66.9% in the 4th quarter. Northern Trust Corp now owns 54,156 shares of the company’s stock valued at $168,000 after acquiring an additional 21,703 shares in the last quarter. Finally, Blue Owl Capital Holdings LP acquired a new position in shares of Marker Therapeutics during the 4th quarter valued at $1,724,000. 22.39% of the stock is owned by institutional investors.

Marker Therapeutics Company Profile

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.